Abstract Number: 74 • 2017 ACR/ARHP Annual Meeting
IL-17 Blockade Attenuates Osteoblastic Activity and Differentiation in Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory bone disease mediated by proinflammatory cytokine secreted by specialized T cells population. The mechanism by which the…Abstract Number: 1521 • 2017 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on 52-Week Clinical Response to Adalimumab in Patients with Ankylosing Spondylitis
Background/Purpose : Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course.1 The actual…Abstract Number: 1549 • 2017 ACR/ARHP Annual Meeting
A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis: 6 – Months Clinical Outcomes from the Czech Biologic Registry Attra
Background/Purpose: A non-medical switch from originator (INX, Remicade) to biosimilar infliximab (CT-P13, Remsima) was conducted in 36 patients with ankylosing spondylitis (AS) in one clinical…Abstract Number: 2514 • 2017 ACR/ARHP Annual Meeting
When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study
Background/Purpose: Osteoporosis and vertebral fractures are recognized complications in axial spondyloarthritis (axSpA). Anteroposterior (AP) DEXA is commonly used to assess spinal bone mineral density (BMD)…Abstract Number: 337 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Flares Were Correctly Predicted By an Algorithm Using Machine-Learning Statistics on Activity Tracker Data on Steps, in a Longitudinal 3-Month Study of 170 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA)
Background/Purpose: The natural history of RA and axSpA comprises periods of low disease activity and flares. However, there are few data linking patient-reported flares to…Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…Abstract Number: 2517 • 2017 ACR/ARHP Annual Meeting
The Usefulness of Trabecular Bone Score in Assessing the Bone Strength and Fracture Risk of Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a disease characterized by spinal osteoproliferation (syndesmophytosis) and the general trabecular bone loss with increased fracture risk. Syndesmophyts in spine…Abstract Number: 577 • 2017 ACR/ARHP Annual Meeting
The Value of C-Reactive Protein As a Predictor of Radiographic Spinal Progression Is Strongly Dependent on β-Fibrinogen and Factor XIII a-Subunit Genotypes in Patients with Axial Spondyloarthritis
Background/Purpose: It has been shown in the past that inflammatory activity (i.e., elevated C-reactive protein) predicts radiographic spinal progression in patients with axial spondyloarthritis (axSpA).…Abstract Number: 1526 • 2017 ACR/ARHP Annual Meeting
Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Background/Purpose: An overall low rate of spinal radiographic progression with the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was reported with secukinumab (SEC), a fully…Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…Abstract Number: 2519 • 2017 ACR/ARHP Annual Meeting
Characteristics of Eye Diseases in Patients with Ankylosing Spondylitis in Korea: A Single-Center Survey
Background/Purpose: Uveitis is the most common extra-articular manifestation occurring in patients with ankylosing spondylitis (AS). The purpose of this study is to evaluate the characteristics…Abstract Number: 582 • 2017 ACR/ARHP Annual Meeting
Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis
Background/Purpose : A newly developed scoring method for low dose CT (ldCT) of the whole spine, CT Syndesmophyte Score (CTSS), has shown good inter-reader reliability…Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…Abstract Number: 1563 • 2017 ACR/ARHP Annual Meeting
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing Spondylitis (AS) is not only characterized by pathological bone formation leading to ankylosis, but also by bone loss which may lead to vertebral…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 62
- Next Page »